DuPont 2013 Annual Report Download - page 99

Download and view the complete annual report

Please find page 99 of the 2013 DuPont annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 102

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)
F-52
2011 included the following pre-tax benefits (charges):
Agriculture1,2 $(225)
Industrial Biosciences3,4 (79)
Nutrition & Health3,4 (126)
Performance Materials4,5 47
Other4(28)
$ (411)
1. Included a $(50) charge recorded in Research and development expense in connection with a milestone payment associated with a Pioneer licensing agreement.
Since this milestone was reached before regulatory approval was secured by Pioneer, it was charged to Research and development expense.
2. Included a $(175) charge recorded in Other operating charges associated with the company's process to fairly resolve claims associated with the use of
Imprelis®. See Note 16 for additional information.
3. Included a $(182) charge for transaction related costs and the fair value step-up of inventories that were acquired as part of the Danisco transaction, which
impacted the segments as follows: Industrial Biosciences - $(70) and Nutrition & Health - $(112).
4. Included a $(53) restructuring charge primarily related to severance and related benefit costs associated with the Danisco acquisition impacting the segments
as follows: Industrial Biosciences - $(9); Nutrition & Health - $(14); Performance Materials - $(2); and Other - $(28).
5. Included a $49 benefit recorded in Other income, net associated with the sale of a business.